Erschienen in:
01.02.2013 | Editorial
The Increasing Credibility of Sentinel Lymph Node Mapping in Endometrial Cancer
verfasst von:
Nadeem R. Abu-Rustum, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 2/2013
Einloggen, um Zugang zu erhalten
Excerpt
Since the pioneering study of Burke et al. from the MD Anderson Cancer Center, which was published in 1996,
1 many investigators have explored the concept of sentinel lymph node (SLN) mapping in endometrial cancer. Two main issues have hindered progress in this area of research—the debate over the site of injection, with many investigators fixated on the view that a peritumoral injection, either hysteroscopic or fundal, is necessary to map disease, and the limited experience and small number of cases published over the 10 years following Burke’s study (1996–2006). During the past 5 years, however, there has been a progressive, positive change in the way many gynecologic oncologists view the role of SLN mapping in endometrial cancer. This is partly due to the negative results of randomized trials on the therapeutic role of pelvic lymphadenectomy in unselected patients with endometrial cancer and the increasing awareness in the gynecologic oncology community about possible long-term side effects, such as lower extremity lymphedema from extensive lymphadenectomy in elderly patients. What adds to the pro-SLN argument is the lack of consensus on the extent of lymphadenectomy and the optimal anatomic templates (pelvic and aortic/renal) needed to stage these patients. …
